according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.0
 28.09.2024
 5723174-00011
 Date of first issue: 23.04.2020

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Prednisolone / Chloramphenicol Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Veterinary product

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Kilsheelan

Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person

responsible for the SDS

EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Carcinogenicity, Category 2 H351: Suspected of causing cancer.

Reproductive toxicity, Category 1B H360: May damage fertility or the unborn child.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :

Signal word : Danger

Hazard statements : H351 Suspected of causing cancer.

H360 May damage fertility or the unborn child.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.0
 28.09.2024
 5723174-00011
 Date of first issue: 23.04.2020

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label:

Chloramphenicol

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form combustible dust concentrations in air during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Chloramphenicol	56-75-7 200-287-4	Carc. 2; H351 Repr. 1B; H360	>= 1 - < 10
prednisolone	50-24-8 200-021-7	Acute Tox. 4; H302 Repr. 2; H361d STOT RE 1; H372 (Bone marrow, Adrenal gland, Liv- er) Aquatic Chronic 2; H411	>= 0,1 - < 0,25

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.0 28.09.2024 5723174-00011 Date of first issue: 23.04.2020

Basic phenylmercury nitrate	8003-05-2	Acute Tox. 3; H301 Skin Corr. 1; H314	>= 0,0002 - < 0,0025
	080-008-00-9	Eye Dam. 1; H318 Repr. 1B; H360D STOT RE 1; H372 (Kidney) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 EUH071	0,0020
		M-Factor (Acute aquatic toxicity): 100 M-Factor (Chronic aquatic toxicity): 10 Acute toxicity estimate	
		Acute oral toxicity: 100 mg/kg	

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.0 28.09.2024 5723174-00011 Date of first issue: 23.04.2020

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks Suspected of causing cancer.

May damage fertility or the unborn child.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

fighting

Specific hazards during fire- : Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

ucts

5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.0
 28.09.2024
 5723174-00011
 Date of first issue: 23.04.2020

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust. Do not breathe vapours.

Do not swallow.

Avoid contact with eyes.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.0
 28.09.2024
 5723174-00011
 Date of first issue: 23.04.2020

Keep container tightly closed.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national

regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Propylene glycol	57-55-6	TWA	25 ppm 79 mg/m3	FOR-2011- 12-06-1358
Chloramphenicol	56-75-7	TWA	300 μg/m3 (OEB 2)	
	Further information: Eye			
prednisolone	50-24-8	TWA	10 μg/m3 (OEB 3)	Internal
		Wipe limit	100 μg/100 cm ²	Internal
Basic phenylmer- cury nitrate	8003-05-2	TWA	0,02 mg/m3 (Mercury)	FOR-2011- 12-06-1358
	Further information: Substances considered to be reprotoxic, Substances considered to evoke allergies when coming into touch with the eyes or airways or evoking allergies after coming into contact with the skin			

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.0
 28.09.2024
 5723174-00011
 Date of first issue: 23.04.2020

Biological occupational exposure limits

Substance name	CAS-No.	Control parameters	Sampling time	Basis
Basic phenylmercury	8003-05-2	Mercury (Mercury):		AN 361
nitrate		30 µg/g creatinine		
		(Urine)		

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
Propylene glycol	Workers	Inhalation	Long-term local ef- fects	10 mg/m3
	Workers	Inhalation	Long-term systemic effects	168 mg/m3
	Consumers	Inhalation	Long-term local effects	10 mg/m3
	Consumers	Inhalation	Long-term systemic effects	50 mg/m3
Hexadecan-1-ol	Workers	Inhalation	Long-term systemic effects	220 mg/m3
	Workers	Inhalation	Acute systemic effects	220 mg/m3
	Workers	Skin contact	Long-term systemic effects	125 mg/kg bw/day
	Workers	Skin contact	Acute systemic effects	125 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	65 mg/m3
	Consumers	Inhalation	Acute systemic effects	65 mg/m3
	Consumers	Skin contact	Long-term systemic effects	75 mg/kg bw/day
	Consumers	Ingestion		75 mg/kg bw/day
Octadecan-1-ol	Workers	Inhalation	Long-term systemic effects	389 mg/m3
	Workers	Inhalation	Long-term local effects	224 mg/m3
	Workers	Skin contact	Long-term systemic effects	110 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	96 mg/m3
	Consumers	Skin contact	Long-term systemic effects	55 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	55 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Propylene glycol	Fresh water	260 mg/l
	Freshwater - intermittent	183 mg/l
	Marine water	26 mg/l
	Sewage treatment plant	20000 mg/l

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.0 28.09.2024 5723174-00011 Date of first issue: 23.04.2020

	Fresh water sediment	572 mg/kg dry weight (d.w.)
	Marine sediment	57,2 mg/kg dry weight (d.w.)
	Soil	50 mg/kg dry weight (d.w.)
Hexadecan-1-ol	Fresh water sediment	30 mg/kg dry weight (d.w.)
	Marine sediment	3 mg/kg dry weight (d.w.)
	Soil	5,8 mg/kg dry weight (d.w.)
Octadecan-1-ol	Fresh water sediment	56,6 mg/kg dry weight (d.w.)
	Marine sediment	5,66 mg/kg dry weight (d.w.)
	Soil	11,3 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to NS EN 14387

Filter type : Combined particulates and organic vapour type (A-P)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.0
 28.09.2024
 5723174-00011
 Date of first issue: 23.04.2020

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : cream

Colour : No data available

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : May form combustible dust concentrations in air during pro-

cessing, handling or other means.

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : Not applicable

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Vapour pressure : Not applicable

Relative density : No data available

Density : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.0
 28.09.2024
 5723174-00011
 Date of first issue: 23.04.2020

Relative vapour density : Not applicable

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : Not applicable

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form combustible dust concentrations in air during pro-

cessing, handling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact Ingestion

Eye contact

Acute toxicity

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.0 28.09.2024 5723174-00011 Date of first issue: 23.04.2020

Components:

Chloramphenicol:

Acute oral toxicity : LD50 Oral (Rat): 2.500 mg/kg

prednisolone:

Acute oral toxicity : LD50 (Mouse): 1.680 mg/kg

LD50 (Rat): > 3.857 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of :

administration)

LD50 (Rat): 147 mg/kg

Application Route: Subcutaneous

LD50 (Mouse): 767 mg/kg

Application Route: Intraperitoneal

Basic phenylmercury nitrate:

Acute oral toxicity : LD50 (Mouse): > 50 - 300 mg/kg

Remarks: Based on data from similar materials

Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

Skin corrosion/irritation

Not classified based on available information.

Components:

prednisolone:

Remarks : No data available

Basic phenylmercury nitrate:

Result : Corrosive after 4 hours or less of exposure
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Chloramphenicol:

Remarks : Mild eye irritation

prednisolone:

Remarks : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.0
 28.09.2024
 5723174-00011
 Date of first issue: 23.04.2020

Basic phenylmercury nitrate:

Result : Irreversible effects on the eye Remarks : Based on skin corrosivity.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

prednisolone:

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

Chloramphenicol:

Genotoxicity in vitro : Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts

Result: positive

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro) Test system: rat hepatocytes

Result: positive

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Test system: mammalian cells

Result: positive

Genotoxicity in vivo : Test Type: Chromosomal aberration

Species: Mouse

Cell type: Bone marrow

Result: positive

Test Type: Micronucleus test

Species: Mouse

Cell type: Bone marrow

Result: negative

Test Type: Micronucleus test

Species: Rat

Cell type: Bone marrow

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 5723174-00011 Date of first issue: 23.04.2020 4.0

Result: negative

prednisolone:

Genotoxicity in vitro Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Mouse Lymphoma

Result: negative

Test Type: sister chromatid exchange assay

Result: negative

Genotoxicity in vivo Test Type: Mammalian erythrocyte micronucleus test (in vivo

> cytogenetic assay) Species: Rat

Application Route: Oral

Result: negative

Test Type: sister chromatid exchange assay

Species: Humans Result: negative

Carcinogenicity

Suspected of causing cancer.

Components:

Chloramphenicol:

Remarks : IARC: (International Agency for Research on Cancer)

Carcinogenicity - Assess-

ment

: Limited evidence of carcinogenicity in animal studies

prednisolone:

Species Rat Application Route Oral Exposure time 18 Months Result : negative

Reproductive toxicity

May damage fertility or the unborn child.

Components:

Chloramphenicol:

Effects on foetal develop-

ment

Species: Monkey, female

Result: No significant adverse effects were reported

Species: Mouse

Developmental Toxicity: LOAEL: 500 mg/kg body weight Result: Embryo-foetal toxicity, Fetal growth retardation

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.0
 28.09.2024
 5723174-00011
 Date of first issue: 23.04.2020

Species: Rat

Developmental Toxicity: LOAEL: 500 - 2.000 mg/kg body

weight

Result: Embryo-foetal toxicity, Fetal growth retardation, Tera-

togenic effects

Species: Rabbit

Developmental Toxicity: LOAEL: 1.000 mg/kg body weight Result: Embryo-foetal toxicity, Fetal growth retardation

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on sexual function and fertil-

ity, and/or on development, based on animal experiments

prednisolone:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Subcutaneous Fertility: NOAEL: 1 mg/kg body weight

Result: No effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Oral

Developmental Toxicity: LOAEL: 0,5 mg/kg body weight Result: Malformations were observed., Cleft palate

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 30 mg/kg body weight

Result: decreased blood formation

Species: Rat

Application Route: Subcutaneous

Developmental Toxicity: NOAEL: 25 mg/kg body weight

Result: No effects on foetal development

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

Basic phenylmercury nitrate:

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Intraperitoneal injection

Result: positive

Remarks: Based on data from similar materials

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.0
 28.09.2024
 5723174-00011
 Date of first issue: 23.04.2020

STOT - single exposure

Not classified based on available information.

Components:

Chloramphenicol:

Exposure routes : Oral

Target Organs : Blood, Bone marrow

STOT - repeated exposure

Not classified based on available information.

Components:

Chloramphenicol:

Exposure routes : Oral, Inhalation

Target Organs : Blood, Bone marrow, Liver

prednisolone:

Target Organs : Bone marrow, Adrenal gland, Liver

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Basic phenylmercury nitrate:

Exposure routes : Oral Target Organs : Kidney

Assessment : Shown to produce significant health effects in animals at con-

centrations of 10 mg/kg bw or less.

Repeated dose toxicity

Components:

Chloramphenicol:

Species : Dog

Target Organs : Blood, Bone marrow

Symptoms : decrease in appetite, Reduced body weight

prednisolone:

Species : Rat
LOAEL : 0,6 mg/kg
Application Route : Oral
Exposure time : 63 Days
Target Organs : Bone marrow

Species: DogLOAEL: 2,5 mg/kgApplication Route: OralExposure time: 6 WeeksTarget Organs: Adrenal gland

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.0
 28.09.2024
 5723174-00011
 Date of first issue: 23.04.2020

Species : Rabbit
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 24 Weeks
Target Organs : Liver

Basic phenylmercury nitrate:

Species : Rat

NOAEL : < 1,25 mg/kg
Application Route : Ingestion
Exposure time : 2 yr

Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

Components:

Chloramphenicol:

General Information : Target Organs: Blood

Target Organs: Bone marrow

Symptoms: aplastic anemia, confusion, Diarrhoea, Fever,

Headache, Nausea, Vomiting

prednisolone:

Ingestion : Symptoms: sodium retention, Headache, Vertigo, fluid reten-

tion, subcutaneous bleeding, striae, skin atrophy, menstrual

irregularities

SECTION 12: Ecological information

12.1 Toxicity

Components:

prednisolone:

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 85 mg/l

aquatic invertebrates Exposure time: 48 h

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.0
 28.09.2024
 5723174-00011
 Date of first issue: 23.04.2020

Toxicity to algae/aquatic

plants

NOEC (Pseudokirchneriella subcapitata (green algae)): 160

mg/l

Exposure time: 72 h

EC50 (Pseudokirchneriella subcapitata (green algae)): > 160

mg/l

Exposure time: 72 h

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0,23 mg/l Exposure time: 7 d

Species: Ceriodaphnia dubia (water flea)

Basic phenylmercury nitrate:

Toxicity to fish : EC50 (Oncorhynchus mykiss (rainbow trout)): > 0,001 - 0,01

mg/l

Exposure time: 96 h

Remarks: Based on data from similar materials

Toxicity to daphnia and other:

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 0,001 - 0,01 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0,01

- 0,1 mg/l

Exposure time: 96 h

Remarks: Based on data from similar materials

EC10 (Pseudokirchneriella subcapitata (green algae)): > 0,01

- 0,1 mg/l

Exposure time: 72 h

Remarks: Based on data from similar materials

M-Factor (Acute aquatic tox-

icity)

100

Toxicity to microorganisms : NOEC (Bacteria): > 0,001 - 0,01 mg/l

Exposure time: 18 h

Remarks: Based on data from similar materials

Toxicity to fish (Chronic tox-

icity)

NOEC: > 0,0001 - 0,001 mg/l

Exposure time: 32 d

Species: Pimephales promelas (fathead minnow) Remarks: Based on data from similar materials

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: > 0,001 - 0,01 mg/l

Exposure time: 35 d

Species: Mysidopsis bahia (opossum shrimp) Remarks: Based on data from similar materials

M-Factor (Chronic aquatic

toxicity)

: 10

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.0
 28.09.2024
 5723174-00011
 Date of first issue: 23.04.2020

12.2 Persistence and degradability

Components:

Basic phenylmercury nitrate:

Biodegradability : Result: Readily biodegradable.

Remarks: Based on data from similar materials

12.3 Bioaccumulative potential

Components:

prednisolone:

Partition coefficient: n- :

: log Pow: 1,46

octanol/water

Basic phenylmercury nitrate:

Partition coefficient: n-

: log Pow: 1,27

octanol/water

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.0
 28.09.2024
 5723174-00011
 Date of first issue: 23.04.2020

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 5723174-00011 Date of first issue: 23.04.2020 4.0

Remarks Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mix-

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

Conditions of restriction for the following entries should be considered: Number on list 18: Basic phenylmercury nitrate

Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or

not.

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation (Annex XIV)

Regulation (EC) on substances that deplete the ozone

Regulation (EU) 2019/1021 on persistent organic pollu-

tants (recast) Regulation (EU) No 649/2012 of the European Parlia-

of dangerous chemicals

ment and the Council concerning the export and import

major-accident hazards involving dangerous substances.

Not applicable Not applicable

Not applicable

Not applicable

Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

Not applicable

Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

The components of this product are reported in the following inventories:

AICS not determined

DSL not determined

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.0
 28.09.2024
 5723174-00011
 Date of first issue: 23.04.2020

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H301 : Toxic if swallowed. H302 : Harmful if swallowed.

H314 : Causes severe skin burns and eye damage.

H318 : Causes serious eye damage. H351 : Suspected of causing cancer.

H360 : May damage fertility or the unborn child.

H360D : May damage the unborn child.

H361d : Suspected of damaging the unborn child.

H372 : Causes damage to organs through prolonged or repeated

exposure.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.H411 : Toxic to aquatic life with long lasting effects.

EUH071 : Corrosive to the respiratory tract.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard

Carc. : Carcinogenicity
Eye Dam. : Serious eye damage
Repr. : Reproductive toxicity
Skin Corr. : Skin corrosion

STOT RE : Specific target organ toxicity - repeated exposure

AN 361 : Norway. Directive on measures and limit values for physical

and chemical factors in the work environment (biological limit

values).

FOR-2011-12-06-1358 : Norway. Occupational Exposure limits

FOR-2011-12-06-1358 / : Long term exposure limit

TWA

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergen-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Prednisolone / Chloramphenicol Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.0 28.09.2024 5723174-00011 Date of first issue: 23.04.2020

cy Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Sheet cy, http://echa.europa.eu/

Classification of the mixture: Classification procedure:

Carc. 2 H351 Calculation method Repr. 1B H360 Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN